Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Felip, E; Moreno, V; Morgensztern, D; Curigliano, G; Rutkowski, P; Trigo, JM; Calvo, A; Kowalski, D; Cortinovis, D; Plummer, R; Maio, M; Ascierto, PA; Vladimirov, VI; Cervantes, A; Zudaire, E; Hazra, A; T'jollyn, H; Bandyopadhyay, N; Greger, JG; Attiyeh, E; Xie, H; Calvo, E.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2022; 89(4): 499-514 Nº de citas: 20 [doi:10.1007/s00280-022-04414-6]

Majem, M; de las Penas, R; Virizuela, JA; Cabezon-Gutierrez, L; Cruz, P; Lopez-Castro, R; Mendez, M; Mondejar, R; Munoz, MD; Escobar, Y.

SEOM clinical guideline emesis (2021)

Clinical & Translational Oncology. 2022; 24(4): 712-723 Nº de citas: 14 [doi:10.1007/s12094-022-02802-1]

Elez, E; Gomez-Espana, MA; Gravalos, C; Garcia-Alfonso, P; Ortiz-Morales, MJ; Losa, F; Diaz, IA; Grana, B; Toledano-Fonseca, M; Valladares-Ayerbes, M; Polo, E; Salgado, M; De Castro, EM; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, J; Riesco, MD; Rodriguez-Ariza, A; Aranda, E.

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

BRITISH JOURNAL OF CANCER. 2022; 126(6): 874-880 Nº de citas: 6 [doi:10.1038/s41416-021-01638-w]

Echavarria, I; Galindo, JRC; Corral, J; Tain, MPD; Carrasco, FH; Gonzalez-Cruz, VI; Mielgo-Rubio, X; Quintanar, T; Corredor, CR; Segura, PP.

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

Clinical & Translational Oncology. 2022; 24(4): 724-732 Nº de citas: 11 [doi:10.1007/s12094-022-02800-3]

Garcia-Saenz, JA; Martinez-Janez, N; Cubedo, R; Jerez, Y; Lahuerta, A; Gonzalez-Santiago, S; Ferrer, N; Ramos, M; Alonso-Romero, JL; Anton, A; Carrasco, E; Chen, JJ; Neuwirth, R; Galinsky, K; Vincent, S; Leonard, EJ; Slamon, D.

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

CLINICAL CANCER RESEARCH. 2022; 28(6): 1107-1116 Nº de citas: 22 [doi:10.1158/1078-0432.CCR-21-2652]

Alsar, JS; de la Tabla, AGO; Moran, LO; Martin, AJM.

Treatment modalities in cancer-associated venous thromboembolism (VTE)

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2022; 35(1): Nº de citas: 2 [doi:10.1016/j.beha.2022.101354]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Clinical & Translational Oncology. 2022; 24(3): 483-494 Nº de citas: 39 [doi:10.1007/s12094-021-02708-4]

Lopez-Tarruella, S; Echavarria, I; Jerez, Y; Herrero, B; Gamez, S; Martin, M.

How we treat HR-positive, HER2-negative early breast cancer

Future Oncology. 2022; 18(8): 1003-1022 Nº de citas: 25 [doi:10.2217/fon-2021-0668]

Calvo, A; Gonzalez-Hidalgo, M; Terleira, A; Fernandez, N; Portoles, A.

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers

Journal of Clinical Medicine. 2022; 11(4): Nº de citas: 1 [doi:10.3390/jcm11041141]

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arija, JA; Marin, MR; Lisyanskaya, A; Poka, RL; Markowska, J; Cebotaru, C; Herraez, AC; Colombo, N; Kutarska, E; Hall, M; Jacobs, A; Ahrens-Fath, I; Baumeister, H; Zurlo, A; Sehouli, J.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

ESMO Open. 2022; 7(1): Nº de citas: 17 [doi:10.1016/j.esmoop.2021.100311]

Muino, CB; Martin, M; del Monte-Millan, M; Garcia-Saenz, JA; Lopez-Tarruella, S.

HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cancers. 2022; 14(3): Nº de citas: 3 [doi:10.3390/cancers14030512]

Schoffski, P; Tan, DSW; Martin, M; Ochoa-de-Olza, M; Sarantopoulos, J; Carvajal, RD; Kyi, C; Esaki, T; Prawira, A; Akerley, W; De Braud, F; Hui, RN; Zhang, T; Soo, RA; Maur, M; Weickhardt, A; Krauss, J; Deschler-Baier, B; Lau, A; Samant, TS; Longmire, T; Chowdhury, NR; Sabatos-Peyton, CA; Patel, N; Ramesh, R; Hu, TC; Carion, A; Gusenleitner, D; Yerramilli-Rao, P; Askoxylakis, V; Kwak, EL; Hong, DS.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer. 2022; 10(2): Nº de citas: 138 [doi:10.1136/jitc-2021-003776]

Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(3): 282-293 Nº de citas: 203 [doi:10.1200/JCO.21.02554]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Butler, MO; Hill, A; Marquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bas, T; Ritchings, C; Larkin, J; Hodi, FS.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 127-137 Nº de citas: 935 [doi:10.1200/JCO.21.02229]

Lenz, HJ; Van Cutsem, E; Limon, ML; Wong, KYM; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Luppi, G; Cardin, DB; Dragovich, T; Shah, U; Abdullaev, S; Gricar, J; Ledeine, JM; Overman, MJ; Lonardi, S.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 161-170 Nº de citas: 579 [doi:10.1200/JCO.21.01015]

Perez-Hernandez, C; Canovas, ML; Carmona-Bayonas, A; Escobar, Y; Margarit, C; Cervantes, JFM; Quintanar, T; Alfonso, AS; Virizuela, J.

A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

Journal of Pain Research. 2022; 15: 2181-2196 Nº de citas: 3 [doi:10.2147/JPR.S365351]

Alfano, F; Cordero-Grande, L; Ortuno, JE; Garcia, KF; Garcia-Sevilla, M; Zamora, OB; Conde, MH; Lizarraga, S; Santos, A; Pascau, J; Ledesma-Carbayo, MJ.

Breast Tumor Localization by Prone to Supine Landmark Driven Registration for Surgical Planning

IEEE Access. 2022; 10: 122901-122911 Nº de citas: 5 [doi:10.1109/ACCESS.2022.3223658]

Calvo-Lopez, T; Paz-Cabezas, M; Llovet, P; Ibanez, MD; Sastre, J; Alonso-Orduna, V; Vieitez, JM; Yubero, A; Vera, R; Asensio-Martinez, E; Garcia-Alfonso, P; Aranda, E; Diaz-Rubio, E; Perez-Villamil, B.

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Cancer Biomarkers. 2022; 34(2): 201-210 Nº de citas: 7 [doi:10.3233/CBM-210353]